INVESTOR ALERT: Investigation of Aquestive Therapeutics, Inc. (AQST) by Holzer & Holzer, LLC

Core Insights - Holzer & Holzer, LLC is investigating whether Aquestive Therapeutics, Inc. complied with federal securities laws following the FDA's notice regarding deficiencies in the New Drug Application for Anaphylm™ [1] - The FDA's notice indicates that the identified deficiencies preclude discussion of labeling and post-marketing commitments for Anaphylm™, which is intended for treating severe allergic reactions [1] - Following the FDA's announcement, the stock price of Aquestive Therapeutics experienced a decline [1] Company Information - Aquestive Therapeutics, Inc. is focused on developing treatments for severe allergic reactions, including anaphylaxis, through its product candidate Anaphylm™ [1] - Holzer & Holzer, LLC is a law firm that specializes in representing shareholders and investors in securities litigation, including class action and derivative litigation [3] - The firm has a history of recovering hundreds of millions of dollars for shareholders affected by corporate misconduct since its founding in 2000 [3]